ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
31 hedge funds and large institutions have $6.26M invested in ImmunoCellular Therapeutics, Ltd. in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
3% less funds holding
Funds holding: 32 → 31 (-1)
17% less capital invested
Capital invested by funds: $7.54M → $6.26M (-$1.28M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
+$622K |
| 2 |
Renaissance Technologies
New York
|
+$605K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$145K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$29.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.2M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$948K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$178K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$112K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$60K |
IMUC Hedge Fund Activity: Q2 2015 in Review
31 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q2 2015, worth a combined $6.26M — down 17% from $7.54M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMUC and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 6 added.
The largest buyer was Bailard, opening a new position worth an estimated $622K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.2M sold.
- 31 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q2 2015, down from 32 in Q1 2015.
- Funds reported $6.26M of ImmunoCellular Therapeutics, Ltd. stock for Q2 2015, down 17% quarter-over-quarter.
- 4 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q2 2015 and 5 closed out, a net change of -1 holder.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q2 2015 was Bailard, an estimated $622K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q2 2015 was Armistice Capital, an estimated $1.2M sold.
Based on aggregated 13F filings for Q2 2015.